文献速递头颈与中枢神经肿瘤消化系统肿瘤

抗表皮生长因子受体抗体药物偶联物MRG003治疗晚期实体瘤患者的安全性评估:1期非随机临床试验

Evaluation of Safety of Treatment With Anti-Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2022-01-01

这项1期非随机多中心研究分1a剂量递增和1b剂量扩展两部分,纳入晚期实体瘤患者。1a确定推荐剂量为2.5 mg/kg;1b中EGFR阳性鼻咽癌和头颈部鳞癌客观缓解率分别为44%和40%,结直肠癌为0%。作者认为MRG003安全性可控,在鼻咽癌和头颈部鳞癌中显示有前景的抗肿瘤活性。

要点

  • 1a期确定MRG003推荐剂量为2.5 mg/kg,每3周静脉给药。
  • 31%患者报告3级及以上治疗相关不良事件,包括低钠血症、白细胞减少、中性粒细胞减少等。
  • 1b期鼻咽癌客观缓解率44%、头颈部鳞癌40%、结直肠癌0%。

核心结论

  • 作者认为,MRG003在EGFR阳性鼻咽癌和头颈部鳞癌患者中显示可控的安全性和有前景的抗肿瘤活性。

研究设计与样本

  • 非随机、开放标签、单臂、1期、多中心研究,分1a剂量递增和1b剂量扩展两部分。
  • 1a期纳入22例晚期或转移性实体瘤患者,未进行EGFR预筛选;1b期纳入39例EGFR阳性难治性晚期头颈部鳞癌、鼻咽癌和结直肠癌患者。
  • 研究在中国7个中心开展,时间为2018年4月11日至2021年3月29日(数据截止日期),数据分析于2021年4月至2021年6月进行。
  • 1a期静脉给予MRG003 0.1至2.5 mg/kg,每3周一次;1b期给予1a期确定的推荐剂量。

主要发现

  • 1a期22例患者平均(范围)年龄54.5(32.0-67.0)岁,女性9例(41%);1b期39例患者平均(范围)年龄50.4(27.0-75.0)岁,女性8例(21%)。
  • 推荐剂量确定为2.5 mg/kg。
  • 89%的不良事件与MRG003治疗相关,大多数不良事件为1至2级。
  • 19例患者(31%)报告3级及以上治疗相关不良事件,包括低钠血症、白细胞减少、中性粒细胞减少、天冬氨酸氨基转移酶升高和发热性中性粒细胞减少。
  • 1a期1例患者(5%)达到部分缓解,5例(23%)达到疾病稳定;1b期8例患者(21%)达到确认的部分缓解,12例(31%)达到疾病稳定。

关键数值与推荐

  • 1a期主要终点为剂量限制性毒性,1b期主要终点为客观缓解率。
  • 安全性、耐受性、免疫原性和药代动力学为评估指标,肿瘤评估采用RECIST 1.1。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The antibody drug conjugate drug MRG003 comprises an anti-epidermal growth factor receptor (EGFR) humanized immunoglobulin G1 monoclonal antibody that is conjugated with monomethyl auristatin E via a valine-citrulline linker. There is currently insufficient evidence of this drug's safety and efficacy. OBJECTIVE: To evaluate the safety and maximum tolerated dose of MRG003 in a phase 1a study and investigate the preliminary antitumor activity in EGFR-expressing patients in a phase 1b study. DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized open-label, single-arm, phase 1, multicenter study of solid tumors was divided into 2 parts, phase 1a dose escalation and phase 1b dose expansion. Patients with advanced or metastatic solid tumors who had failed outcomes from or were not able to receive standard treatment were enrolled in phase 1a without EGFR prescreening. Phase 1b recruited EGFR-positive patients with refractory advanced squamous cell carcinomas of the head and neck (SCCHN), nasopharyngeal carcinoma (NPC), and colorectal cancer (CRC). This study was conducted at 7 Chinese centers between April 11, 2018, and March 29, 2021 (data cutoff date). Data analysis took place between April 2021 and June 2021. INTERVENTIONS: An intravenous dose of 0.1 to 2.5 mg/kg of MRG003 was administered every 3 weeks during phase 1a. During phase 1b, patients were administered the recommended dose identified in phase 1a. MAIN OUTCOMES AND MEASURES: The primary end points were dose-limiting toxic effects in phase 1a and objective response rate in phase 1b. The safety, tolerability, immunogenicity, and pharmacokinetics of MRG003 were assessed. Tumor assessment was evaluated by RECIST 1.1. RESULTS: Twenty-two patients (mean [range] age, 54.5 [32.0-67.0] years; 9 women [41%]) were enrolled in phase 1a and 39 patients (mean [range] age, 50.4 [27.0-75.0] years; 8 women [21%]) in phase 1b. The recommended dose was identified as 2.5 mg/kg. Eighty-nine percent of adverse events (AEs) were associated with MRG003 treatment, and most AEs were grade 1 to 2. Nineteen patients (31%) reported grade 3 or greater treatment-related AEs, including hyponatremia, leukocytopenia, neutropenia, increased aspartate aminotransferase levels, and febrile neutropenia. In phase 1a, 1 patient (5%) achieved a partial response, and 5 (23%) achieved stable disease. In phase 1b, 8 patients (21%) achieved a confirmed partial response, and 12 (31%) achieved stable disease. The objective response rates for SCCHN, NPC, and CRC were 40%, 44%, and 0%, and the disease control rates were 100%, 89%, and 25%, respectively. CONCLUSIONS AND RELEVANCE: The findings of this nonrandomized clinical trial suggest that MRG003 showed a manageable safety profile and promising antitumor activity in patients with EGFR-positive NPC and SCCHN. TRIAL REGISTRATION: Clinicaltrials.gov Identifier: NCT04868344.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Qiu MZ, Zhang Y, Guo Y, et al. Evaluation of Safety of Treatment With Anti-Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial. JAMA Oncol. 2022. PMID: 35511148. doi:10.1001/jamaoncol.2022.0503

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。